Amylyx Pharmaceuticals Announces Nomination of AMX0318 as a Novel, Long-Acting GLP-1 Receptor Antagonist Development Candidate, Identified in Collaboration with Gubra A/S

Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) ("Amylyx" or the "Company") today announced the selection of AMX0318, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist, as a development ...
Medscape

Angiotensin II Receptor Blockers in Older Patients

Older patients with hypertension are often inadequately treated due to misconceptions regarding reasonable goal blood pressures or concerns about treatment side effects. Adequately treating ...

Researchers revive an abandoned depression drug target using structurally novel NK1 receptor inhibitors

For decades, scientists have investigated the neurokinin-1 receptor (NK1R) as a potential target for treating major ...
Medscape

Angiotensin Receptor Blockers May Lead to Worse Outcomes in Celiac Disease

PHILADELPHIA — Patients with celiac disease who take an angiotensin receptor blocker (ARB) may experience worse outcomes, such as increased risk of iron deficiency, diarrhea, and abdominal pain, ...
Healio

Leukotriene receptor antagonists add to efficacy of antihistamines for chronic urticaria

Please provide your email address to receive an email when new articles are posted on . The addition of leukotriene receptor antagonists to antihistamines improved urticaria symptoms. The combination ...